gepotidacin · GEPOTIDACIN MESYLATE 750 mg/1 · Tablet, Film Coated · Oral · GlaxoSmithKline LLC
NDC 00173-0922-38 · 8 TABLET, FILM COATED in 1 BOTTLE · NDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles. Put together: worth watching — several of the pressures that precede supply trouble are present at once.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 00173-0922-45) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 2 quarters since 2024.
Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | GAIN | Mar 25, 2035 |
| exclusivity | NCE | Mar 25, 2030 |
| exclusivity | I-978 | Dec 11, 2028 |
| patent | 12528809 | Dec 13, 2042 |
| patent | 11229646 | Aug 20, 2035 |
| patent | 10702521 | Aug 20, 2035 |
| patent | 8389524 | Feb 12, 2029 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| GlaxoSmithKline LLC | GEPOTIDACIN MESYLATE 750 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Blujepa — NDC 00173-0922-38," retrieved September 3, 2026, https://drugdashboards.com/drug/00173092238.
Free to cite with attribution — see how the data is put together.